Table 1 Baseline clinical characteristics of 50 GIST patients treated with regorafenib
Characteristic | Total, n = 50 |
|---|---|
Age at diagnosis (years) | |
Median (IQR) | 56.0 years (46.0–66.5 years) |
Gender | |
Female | 18 (36%) |
Male | 32 (64%) |
Primary site | |
Stomach | 21 (42%) |
Small bowel | 21 (42%) |
Large bowel | 2 (4.0%) |
Rectum | 2 (4.0%) |
Mesenteric | 2 (4.0%) |
Oesophageal | 2 (4.0%) |
Line of treatment (regorafenib) | |
3rd line | 38 (76%) |
4th line | 10 (20%) |
≥ 5th line | 2 (4%) |
Tumour size (cm) | |
Median (IQR) | 12.0 (8.0–17.0) |
Mutation profile | |
KIT | 31 (62%) |
Exon 9 | 4 (8%) |
Exon 11 | 24 (48%) |
Exon 11 + 13 | 1 (2%) |
Exon 11 + 17 | 2 (4%) |
PDGFR | 6 (12%) |
Exon 18 | 5 (10%) |
Exon 12 + 18 | 1 (2%) |
WT | 4 (8%) |
Unknown | 9 (18%) |
Reason for discontinuing regorafenib | |
Progressive disease | 31 (62%) |
Toxicity | 10 (20%) |
New comorbidity/contraindication | 3 (6%) |
Death | 2 (4%) |
Surgery planned | 1 (2%) |
Withdrawal of consent to treatment | 1 (2%) |
N/A—patient continues regorafenib | 2 (4%) |
AE | |
Grade ≥ 3 | 23 (46%) |
Best response as per RECIST 1.1 | |
Stable disease | 35 (70%) |
Partial response | 4 (8%) |
Progressive disease | 4 (8%) |
Complete response | 0 (0%) |
Not evaluable | 7 (14%) |